Press Releases

Global Kinetics Corporation’s PKG® Smartwatch Provides Clinically Meaningful Improvement in Parkinson’s Disease Symptom Assessment, Management and Medication Optimization, As Well As Projected Per Patient Cost Savings Data Recently Presented at the 2018 International Congress of Parkinson’s Disease and Movement Disorders

Data Recently Presented at the 2018 International Congress of Parkinson’s Disease and Movement Disorders

Global Kinetics Pty Ltd. (GKC) today announced data recently presented at a poster presentation session during the International Congress of Parkinson’s Disease (PD) and Movement Disorders (MDS), held October 5-9, in Hong Kong, China.

Please read the full press release here

 

The PKG has been recommended by two separate expert panels for routine management of Parkinson's disease.

In the most recent of a series of significant clinical milestones, Global Kinetics’ innovative wearable technology, the Personal KinetiGraph™ (PKG™), has been recommended by two separate expert panels for routine management of Parkinson’s disease. The publications follow on the heels of the recent announcement by the company that the American Medical Association (AMA) has issued a set of new Category III Current Procedural Terminology® (CPT®) codes that become effective on January 1, 2019.

Please read full press release here

Leading Parkinson’s measurement company Global Kinetics reaches major milestone with issue of US CPT III codes.

Global Kinetics Pty Ltd. (GKC) today announced that the American Medical Association (AMA) has issued a set of new Category III Current Procedural Terminology® (CPT®) codes that describe the services provided by the Company’s FDA-cleared and CE-marked Personal KinetiGraph™ (PKG™).

Please read the full press release here

Treat-to-Target Trial - 11 April 2018

GKC has successfully secured funding from the high profile and leading international funder in Parkinson’s - The Michael J. Fox Foundation – as well as the Shake It Up Australia Foundation and Parkinson’s Victoria, to support a global trial to evaluate the use of objective targets to guide the treatment and management of Parkinson’s disease.

Please read the full press release here

 

Study published in Nature uses PKG™ and targets to improve patient outcomes

Reported in Natures npj Parkinson's Disease, the study demonstrates the use of objective targets and measurement with the PKG system significantly improved clinical care and quality of life for people with Parkinson's.

Key findings of the study were that most people with PD (78%) are living with symptoms considered to be outside the target range including excessive bradykinesia, dyskinesia and tremor. Using targets and objective assessment, clinicians were able to improve treatment options in more than half of the study participants.

To read the full article, please click here